{"type":"rich","published":"2026-11-14 23:19:25","height":"190","author_name":"marfan-info","provider_url":"https://hatena.blog","title":"\u30ed\u30a4\u30b9\u30fb\u30c7\u30a3\u30fc\u30c4\u75c7\u5019\u7fa4\u306e2026\u5e74\u7248\u624b\u5f15\u304d\u306b\u3064\u3044\u3066\u3000\u301c\u795e\u7d4c\u8840\u7ba1\u7cfb\uff08\u8133\u30fb\u9838\u90e8\u8840\u7ba1\uff09\u306e\u8a55\u4fa1\u3068\u5bfe\u5fdc\u301c","provider_name":"Hatena Blog","url":"https://marfan-info.hatenablog.com/entry/2026/11/14/231925","blog_url":"https://marfan-info.hatenablog.com/","version":"1.0","width":"100%","blog_title":"\u6d77\u5916\u30de\u30eb\u30d5\u30a1\u30f3\u60c5\u5831 | Global Marfan Updates","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fmarfan-info.hatenablog.com%2Fentry%2F2026%2F11%2F14%2F231925\" title=\"\u30ed\u30a4\u30b9\u30fb\u30c7\u30a3\u30fc\u30c4\u75c7\u5019\u7fa4\u306e2026\u5e74\u7248\u624b\u5f15\u304d\u306b\u3064\u3044\u3066\u3000\u301c\u795e\u7d4c\u8840\u7ba1\u7cfb\uff08\u8133\u30fb\u9838\u90e8\u8840\u7ba1\uff09\u306e\u8a55\u4fa1\u3068\u5bfe\u5fdc\u301c - \u6d77\u5916\u30de\u30eb\u30d5\u30a1\u30f3\u60c5\u5831 | Global Marfan Updates\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","description":"Understanding the Updated LDS Primer for Diagnosis and Management 28:11-29:53 We're going to switch back to some other of our vascular management. So Julie gave us a lot of information on the MRA and CTAs looking at the chest. You know, when we're thinking about neurovascular involvement, we're thin\u2026","author_url":"https://blog.hatena.ne.jp/marfan-info/","categories":["\u30aa\u30f3\u30e9\u30a4\u30f3\u30bb\u30df\u30ca\u30fc","\u30ed\u30a4\u30b9\u30fb\u30c7\u30a3\u30fc\u30c4\u75c7\u5019\u7fa4\uff08LDS\uff09","\u5faa\u74b0\u5668"],"image_url":null}